SCHEMBL2669509

SCHEMBL2669509

Cc1ccc(-c2cccc3c(N)c4c(nc23)CN(C2CCC2)C4=O)nc1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ACVR1 Q04771 5/20 0.40
▸ BMPR1A P36894 4/20 0.40
▸ ACVRL1 P37023 4/20 0.40
▸ ADORA2A P29274 1/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ GRM5 P41594 2/20 0.33
▸ PDE9A O76083 1/20 0.33
▸ CDK5 Q00535 1/20 0.33
▸ CDK5R1 Q15078 1/20 0.33
▸ CDK4 P11802 1/20 0.32
▸ SMO Q99835 1/20 0.32
▸ POLB P06746 1/20 0.32
▸ PARP1 P09874 1/20 0.32
▸ HTT P42858 1/20 0.32
▸ ESR2 Q92731 1/20 0.32
▸ MAPK1 P28482 1/20 0.31
▸ PIK3CA P42336 1/20 0.31
▸ MERTK Q12866 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2669510 0.90 ACVR1 (0.34) ACVR1BMPR1AACVRL1GRM5CDK4
SCHEMBL2661471 0.86 HSD11B1 (0.36) ACVR1BMPR1AACVRL1GRM5POLB
SCHEMBL2669394 0.85 GRM5 (0.36) ACVR1BMPR1AACVRL1KDM4EALDH1A1
SCHEMBL4924879 0.84 TSHR (0.35) ACVR1BMPR1AACVRL1GRM5CDK5
SCHEMBL2669594 0.83 BMPR1A (0.40) ACVR1BMPR1AACVRL1POLBPARP1
SCHEMBL2656099 0.82 PARP1 (0.35) ACVR1BMPR1AACVRL1ALDH1A1GRM5
SCHEMBL2669534 0.82 LCK (0.46) ACVR1BMPR1AACVRL1
SCHEMBL2657795 0.81 HSP90AA1 (0.39) ACVR1BMPR1AACVRL1GRM5POLB
SCHEMBL2661563 0.81 ACVR1 (0.38) ACVR1BMPR1AACVRL1POLBMAPK1
SCHEMBL2660782 0.81 GABRG2 (0.42) ACVR1BMPR1AACVRL1GRM5POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US claimed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US disclosed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US disclosed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US disclosed
WO-2008155572-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS ASTRAZENECA AB (SE) 2008-12-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080318943-A1 Compounds and Uses Thereof - 848 COMT, BACE1, BDNF ACVR1 4057/4885BMPR1A 1929/4885ACVRL1 3949/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback